0:50 - Can you tell me more about guselkumab and how it is used to treat patients with psoriatic arthritis?
3:32 - What were the study designs and methods used in developing the DISCOVER-1 and DISCOVER-2 trials?
5:43 - What were the primary (and any secondary) endpoints evaluated in these trials?
7:00 - What were the results regarding efficacy, safety, and patient-reported outcomes that were presented at the ACR?
9:23 - What does this clinical research mean for both rheumatologists and their patients?
12:07 - Is there anything else you'd like our audience to know about guselkumab or Janssen before we wrap up?